secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2026-11-10T13:21:10+00:00
Accession:  0001104659-26-124829
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

MaxCyte to acquire Akron Bio for $151.8M; Q3 revenue up 49% to $10.2M
---------------------------------------------------------------------

- Deal: $105M cash + 20,639,733 MXCT shares (~$26.8M) + $20M deferred ($10M each in Jan 2028 and Jan 2029); total $151.8M.
- Akron Bio expected 2026 revenue ~$28M and EBITDA $7-8M; products embedded in five approved therapies and >100 clinical programs.
- Q3 2026 revenue $10.2M (+49% YoY): core $8.2M (+27%), SPL $2.0M vs $0.4M; gross margin 83%; net loss $4.8M vs $12.4M.
- FY2026 revenue guidance raised to at least $34.5M (core ~$28M, SPL at least $6.5M); cash $132.7M at Sept 30.
- MidCap facility up to $75M; expects $22M drawn at close. Deal needs HSR and Nasdaq listing approval, no stockholder vote; targeted before end-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/0001104659-26-124829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/tm2629420d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-124829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer